share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 27 16:05
Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the submission of its tenth patent application under the Patent Cooperation Treaty (PCT) in collaboration with SciSparc Ltd., a clinical-stage pharmaceutical company. The patent application, announced on March 27, 2024, pertains to a novel composition of Clearmind's MEAI compound with SciSparc's CannAmide™ active ingredient, aimed at preventing and treating depression. This follows a provisional patent application previously filed with the USPTO. The global depression and anxiety disorders treatment market is projected to grow significantly, reaching USD 41.83 billion by 2034. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed confidence in the potential of their proprietary drugs to impact patients with various forms of depression, including treatment-resistant cases. The company's intellectual property strategy focuses on developing novel psychedelic drugs to address unmet mental health needs. Clearmind's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols CMND and CWY, respectively.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the submission of its tenth patent application under the Patent Cooperation Treaty (PCT) in collaboration with SciSparc Ltd., a clinical-stage pharmaceutical company. The patent application, announced on March 27, 2024, pertains to a novel composition of Clearmind's MEAI compound with SciSparc's CannAmide™ active ingredient, aimed at preventing and treating depression. This follows a provisional patent application previously filed with the USPTO. The global depression and anxiety disorders treatment market is projected to grow significantly, reaching USD 41.83 billion by 2034. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed confidence in the potential of their proprietary drugs to impact patients with various forms of depression, including treatment-resistant cases. The company's intellectual property strategy focuses on developing novel psychedelic drugs to address unmet mental health needs. Clearmind's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols CMND and CWY, respectively.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more